Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | MicrobiomeTrials
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
TERMINATEDPHASE3INTERVENTIONAL
Trial Details
Start: 2020-06-08Est. Completion: 2023-05-31
Enrollment target: 137 participants
Locations
University of California LA, Los Angeles, California, United States
Hematology and Oncology Clinic, Baton Rouge, Louisiana, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Park Nicollet Institute, Saint Louis Park, Minnesota, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Novartis Investigative Site, Rosario, Santa Fe Province, Argentina
Novartis Investigative Site, CABA, Argentina
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Nedlands, Western Australia, Australia
Novartis Investigative Site, Innsbruck, Tyrol, Austria
Novartis Investigative Site, Leoben, Austria
Novartis Investigative Site, Barretos, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Plovdiv, Bulgaria
Novartis Investigative Site, Hefei, Anhui, China
Novartis Investigative Site, Shijiazhuang, Hebei, China
Other microbiome trials you might be interested in